Comments to FDA: Remote Regulatory Assessments Draft Guidance

Docket Number:

FDA-2022-D-0810

CHPA appreciates the opportunity to provide comments on FDA Remote Regulatory Assessments Draft Guidance.

Issues:

OTC Medicines